# The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

> **NCT07069725** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 12 (estimated)

## Conditions studied

- Liver Fibrosis
- Hepatic Cirrhosis

## Interventions

- **DRUG:** AZD2389
- **DIAGNOSTIC_TEST:** PET scan and radioligand

## Key facts

- **NCT ID:** NCT07069725
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2026-07-13
- **Final completion:** 2026-07-13
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07069725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07069725, "The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07069725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*